Thomas Brevig
Overview
Explore the profile of Thomas Brevig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Correll C, Dombi Z, Barabassy A, Nemeth G, Brevig T, McIntyre R
Eur Neuropsychopharmacol
. 2024 Aug;
88:31-39.
PMID: 39121713
Lacking biomarkers in psychiatry calls for a valid and reliable assessment of psychopathology across mental disorders that is easy to use, bridges research and clinical care, and that can capture...
2.
Lipton R, Buse D, Nahas S, Tietjen G, Martin V, Lof E, et al.
J Neurol
. 2023 Aug;
270(12):5692-5710.
PMID: 37615752
Background: In individuals with migraine, attacks may increase in frequency, severity, or both. Preventing migraine progression has emerged as a treatment goal in headache subspecialty practice, but there may be...
3.
Starling A, Kolbet M, Cady R, Brevig T
Pain Manag
. 2023 Jun;
13(6):317-327.
PMID: 37357842
What Is This Summary About?: This is a summary of three articles describing preventive treatment of migraine in participants with a diagnosis of both chronic migraine and medication-overuse headache in...
4.
Starling A, Cowan R, Buse D, Diener H, Marmura M, Hirman J, et al.
Headache
. 2023 Jan;
63(2):264-274.
PMID: 36633219
Objective: To evaluate the effect of eptinezumab on patient-reported outcomes in patients with chronic migraine (CM) and medication-overuse headache (MOH). Background: MOH is a secondary headache disorder commonly occurring in...
5.
Cowan R, Marmura M, Diener H, Starling A, Schim J, Hirman J, et al.
J Headache Pain
. 2022 Sep;
23(1):115.
PMID: 36068494
Background: Patients with chronic migraine (CM) treated with eptinezumab in the PROMISE-2 trial achieved greater reductions in migraine and headache frequency, impact, and acute headache medication (AHM) use than did...
6.
Buse D, Winner P, Charleston 4th L, Hirman J, Cady R, Brevig T
J Headache Pain
. 2022 Feb;
23(1):29.
PMID: 35189811
Background: A clinical ability to describe the response trajectory of patients receiving preventive migraine treatment could expedite and improve therapeutic management decisions. This post hoc analysis of the PROMISE-2 study...
7.
Ailani J, Winner P, Hartry A, Brevig T, Bog M, Lassen A, et al.
Headache
. 2022 Feb;
62(3):374-382.
PMID: 35187644
Objective: The objective of this study was to ascertain to what extent adults with migraine value an early onset of efficacy for preventive migraine treatments. Background: In placebo-controlled clinical trials,...
8.
Lipton R, Charleston 4th L, Tassorelli C, Brevig T, Hirman J, Cady R
J Headache Pain
. 2022 Feb;
23(1):23.
PMID: 35130836
Background: PROMISE-1 and PROMISE-2 evaluated the preventive efficacy, tolerability, and safety of eptinezumab, a calcitonin gene-related peptide-targeted monoclonal antibody, in adults with episodic (EM) and chronic migraine (CM), finding significant...
9.
Marmura M, Diener H, Cowan R, Tepper S, Diamond M, Starling A, et al.
Headache
. 2021 Sep;
61(9):1421-1431.
PMID: 34551130
Objective: This post hoc analysis in patients medically diagnosed with chronic migraine (CM) and medication-overuse headache (MOH) evaluated reductions in the use of acute headache medication (AHM) and sustained changes...
10.
Smith T, Spierings E, Cady R, Hirman J, Schaeffler B, Shen V, et al.
J Headache Pain
. 2021 May;
22(1):46.
PMID: 34034644
No abstract available.